Dapagliflozin Effects on Epicardial Fat
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.
Also called NCT02235298
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT02235298
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02235298. Randomized; triple masking; primary purpose treatment. Start 2015-09 (actual); primary completion 2020-09-10 (actual). Results posted on 2021-02-16.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dapagliflozin Effects on Epicardial Fat
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Placebo
- Lead sponsor
- University of Miami
- Collaborator
- AstraZeneca
Record details
- Record id
cardio:ct-nct02235298- Content hash
b6944fa29bfae33febf9064c39ed66351022e64dcac10912bb5e5f7c508a9b70